Abstract
IgA nephropathy (IgAN) is a leading cause of kidney failure with diverse clinical presentations and treatment responses, particularly to corticosteroids, with conflicting evidence. Due to potentially severe side effects and heterogenous responses more individualized approaches are needed. We developed a causal machine learning framework for predicting individualized treatment effects of corticosteroids in IgAN by integrating clinical variables, histopathological scores, and deep learning-based biomarkers from digitized kidney biopsies (pathomics) of 1,022 patients from eight retrospective international cohorts. At the cohort-level, corticosteroids showed no significant effect on five-year kidney survival. However, the framework identified subpopulations with and without significant treatment benefit, improving progression-free kidney survival and also reducing overtreatment in low-benefit patients. Pathomics highlighted tubulointerstitial inflammation and glomerular tuft deformation as predictors of corticosteroid response. Our framework offers a blueprint for precision therapy in IgAN, supporting clinical decision-making in the era of emerging targeted treatments.
Competing Interest Statement
JF received consultancy and/or lecture honoraria from Alexion, AstraZeneca, Biogen, Boehringer, CSL Vifor, Novartis, Otsuka, Roche, Stadapharm, Vera Therapeutics and Vertex. RK is a founder, shareholder, and board member of Sequantrix GmbH, a member of the scientific advisory board of Hybridize Therapeutics and has received honoraria for advisory boards and talks from Bayer, Chugai, Pfizer, Roche, Genentech, Lilly, and GSK and has received research funding from Travere Therapeutics, Galapagos, Novo Nordisk and Ask Bio. PB received consulting and lecture fees from CSL Vifor, Otsuka, Novartis, Bristol Myers Squibb, Roche, Novo Nordisk, Astellas, and aetherAI none of which was relevant to this work. The other authors declare no competing interests.
Funding Statement
This study was supported by the German Research Foundation (DFG, Project IDs 322900939 & 445703531), European Research Council (ERC Consolidator Grant No 101001791), the Federal Ministry of Education and Research (BMBF, STOP-FSGS-01GM2202C), and the Innovation Fund of the Federal Joint Committee (Transplant.KI, No. 01VSF21048).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of RWTH Aachen University gave ethical approval for this work (EK-No. 125/25).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
ϕ VALIGA, CureGN, NURTuRE & AI4IgAN contributor information are provided in the Supplement
↵§ Shared senior authors
Data and code availability
Whole slide image files and clinical data used in this study are available under restricted access for privacy protection reasons. Access can be obtained by directly contacting the corresponding author who can distribute requests to the collaborators involved who contributed data. Alternatively, to obtain access for individual datasets, all included study groups and contributing collaborators are provided in Supplementary Table 10. In general, requests will be evaluated within a timeframe of 4 weeks based on institutional and trial policies.
Annotated code on model derivation and validation as well as all subsequently performed analyses is available under GitLab (https://git-ce.rwth-aachen.de/labooratory-ai/igan-ite-prediction).
